Small activating RNA upregulates NIS expression: promising potential for hepatocellular carcinoma endoradiotherapy
Small activating RNA upregulates NIS expression: promising potential for hepatocellular carcinoma endoradiotherapy
复制标题
小激活 RNA 上调 NIS 表达：肝细胞癌腔内放射治疗的前景广阔。
DOI：
10.1038/cgt.2016.36
复制
发表时间：
2016-10-01
影响因子：
6.4
通讯作者：
Ye, Y.
中科院分区：
文献类型：
--
作者：
Xia, W.;Li, D.;Ye, Y.
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. worldwide. Currently, the clinical strategies available for the treatment of HCC remain insufficient for the poor prognosis. Sodium/iodide symporter (NIS)-based radioiodine therapy is proposed as a promising therapeutic strategy for the treatment of HCC. However, it is difficult for HCC cells to trap iodine for the lower expression of NIS. Small activating RNA (saRNA) is a newly identified small double-stranded RNA (dsRNA) that can induce endogenous gene expression by targeting promoter sequences. Here, we designed an saRNA (saRNA-482) that targeted the NIS promoter sequences. In the cultured HepG2 cells and Hep3B cells, the expressions of NIS were upregulated after transfection of saRNA-482. In addition, the uptake of I-125 increased in the cultured HepG2 and Hep3B cells transfected with saRNA-482. Furthermore, the cell viabilities were significantly inhibited in the saRNA-482-transfected HepG2 and Hep3B cells after I-131 treatment. Meanwhile, the apoptosis of saRNA-482-transfected HepG2 and Hep3B cells significantly increased after I-131 treatment. The results suggest that RNA activation-mediated upregulation of NIS may have an endoradiotherapeutic potential in the treatment of HCC.
